Subscribe to our mailing list

Express Scripts sells unit tied to expensive drug

Express Scripts is trimming some of its ties to a $35,000-a-vial medicine made by Mallinckrodt, selling a unit that helps patients access some high-priced drugs.

Avista Capital Partners, a private equity firm, will buy Express Scripts’ United BioSource division, the firms said. United BioSource’s website says it helps “maximize product access and commercialization,” helps drug companies “overcome access and adherence challenges” and provides drug testing services.

It also runs a free drug program that gives away Acthar to patients who can’t afford it, Express Scripts said this year.

Powered by WPeMatico

Author: admin

VN:F [1.9.22_1171]
Rating: 0.0/10 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)